New perspectives in designs of novel multi-target agents against cancer may be developed on the basis of the recent studies of CA-4 hybrids with therapeutic agents, i.e., cyclooxygenase-2 inhibitors, ER ligands, HPAC inhibitors, and anticancer medications, cisplatin, and doxorubicin. This evidence concerns the gene PTGS2 and cancer.